Equity Overview
Price & Market Data
Price: $1.64
Daily Change: -$0.04 / 2.44%
Range: $1.61 - $1.68
Market Cap: $53,615,536
Volume: 12,288
Performance Metrics
1 Week: 23.68%
1 Month: 4.78%
3 Months: -15.21%
6 Months: -81.09%
1 Year: -85.96%
YTD: -56.60%
Company Details
Employees: 81
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.